The hemophilia market is expected to experience significant growth due to advancements in gene therapy, innovative treatments, and an increasing focus on personalized medicine. Rising awareness and ...

The government has set aside £11.8bn to compensate victims of the infected blood scandal, after a public inquiry found the ...

Novo Nordisk has shared positive results from a late-stage study of its investigational haemophilia A therapy Mim8 in ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/19.CcrFU5Zy.js ...

Sobi’s Sanofi-partnered efanesoctocog alfa has been approved by the Medicines and Healthcare products Regulatory Agency (MHRA ...

Novo Nordisk today announced interim results from the phase 3 FRONTIER3 trial of 70 children (aged 1-11 years old) with haemophilia A with and without inhibitors. The trial initially assessed ...

The data showed that Mim8 was well-tolerated and efficacious in children with haemophilia A with and without inhibitors. In part one of the FRONTIER3 study, participants with haemophilia A received ...

Novo Nordisk’s bispecific antibody Mim8 prevented bleeding events and caused no adverse safety events in the Phase III ...

That was before the spectacular success of Hemlibra, a bispecific antibody-based drug that mimics the function of Factor VIII by bridging clotting factors on either side of it in the clotting pathway.

People with haemophilia A have a shortage of a clotting agent called Factor VIII, while people with haemophilia B do not have enough Factor IX. In the 1970s, a new treatment using donated human ...

The liver is the site of synthesis of all clotting factors except factor VIII; therefore in liver disease there will be prolonged values due to a lack of factor production. Transfusing the patient ...